Figure 2.
Figure 2. Ring1A/B are required for maintenance of AML stem cells. Secondary recipients of MOZ-TIF2 AML mice that received a secondary transplant of MOZ-TIF2−transduced Ring1A−/−;Ring1Bf/f;CreERT2 BM cells were treated with tamoxifen or corn oil (vehicle) for 5 consecutive days when the proportion of GFP+ MNCs in peripheral blood reached 50%. On the day following the last treatment, BM-MNCs were harvested and analyzed for quantification of L-GMP (A), Gr1+ (B), and Mac1− MCSFR+ (C) cells by flow cytometry (mean ± SD, *P < .01, n = 4), or transplanted into sublethally irradiated recipient mice. (D) Kaplan-Meier survival curve. Tamo, tamoxifen.

Ring1A/B are required for maintenance of AML stem cells. Secondary recipients of MOZ-TIF2 AML mice that received a secondary transplant of MOZ-TIF2−transduced Ring1A−/−;Ring1Bf/f;CreERT2 BM cells were treated with tamoxifen or corn oil (vehicle) for 5 consecutive days when the proportion of GFP+ MNCs in peripheral blood reached 50%. On the day following the last treatment, BM-MNCs were harvested and analyzed for quantification of L-GMP (A), Gr1+ (B), and Mac1− MCSFR+ (C) cells by flow cytometry (mean ± SD, *P < .01, n = 4), or transplanted into sublethally irradiated recipient mice. (D) Kaplan-Meier survival curve. Tamo, tamoxifen.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal